Metraipolis › archive › dc_37bfde9b74fb

Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL — Europe PMC PMID:41267399

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41267399
DOI
10.1016/j.ymthe.2025.11.026
License (as archived)
solo-consultazione
Archived
2026-11-08T11:00:57.373Z
SHA-256 of the archived text
773c6f1a1998baaa9c5f95f9804e752c16706bb03608b2809074b926ead2495b
Stable URL of this page
https://metraipolis.com/documento/dc_37bfde9b74fb

How to cite

Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL — Europe PMC PMID:41267399 — Europe PMC (en), https://europepmc.org/article/MED/41267399 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_37bfde9b74fb (Metraipolis archive dc_37bfde9b74fb, sha256 773c6f1a1998baaa9c5f95f9804e752c16706bb03608b2809074b926ead2495b)
BibTeX
@misc{dc37bfde9b74fb,
  title = {Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL — Europe PMC PMID:41267399},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41267399},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_37bfde9b74fb; sha256 773c6f1a1998baaa9c5f95f9804e752c16706bb03608b2809074b926ead2495b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41267399. Agents can read the archived copy with the MCP tool read_document.